Interferon beta 1-a in multiple sclerosis: Experience of one year in 62 patients;Interferon beta 1-a na esclerose multipla: Experiencia de um ano em 62 pacientes

Arquivos de Neuro-Psiquiatria

Volumn 58, Issue 2 B, 2000, Pages 452-459

  Tilbery, Charles Peter ^a   Felipe, Eduardo ^a   Moreira, Marcos A ^a   Mendes, Maria F ^a   França, Andrea S ^a  

^a NONE

Author keywords

Interferon beta 1 a; Multiple sclerosis; Treatment

Indexed keywords

BETA1A INTERFERON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; PATIENT COMPLIANCE; RELAPSE; TREATMENT OUTCOME;

EID: 0033930319     PISSN: 0004282X     EISSN: None     Source Type: Journal    
DOI: 10.1590/s0004-282x2000000300009     Document Type: Article

References (38)

1. Tsukada N, Matsuda M, Myyagi K, Yanagisawa N. In vitro intrecellular adhesion molecule-1 expression on brain endothelial cells in multiple sclerosis. J. Neuroimmunol. 1994;49:181-187.
2. Canella B, Raine CS. The adhesion molecule and cytokine profile of multiple sclerosis lesions. Ann. Neurol. 1995;37:424-415.
3. Ebers GC. Treatment of multiple sclerosis. Lancet 1994;343:275-279.
4. Kinkel RP, Goodkin De. Immunotherapy for multiple sclerosis:a review of the clinical experience. Clin Immunother 1994;1:117-134.
5. Jacobs L, Munschauer FE. Intrathecal interferon reduces exacerbations of multiple sclerosis. Science 1981;214:1026-1028.
6. The Interferon B Multiple Sclerosis Study Group. Clinical results of a multicenter, randomized, double/blind placebo controlled trial. Neurology 1993;43:655-661.
7. Poser CM, Paty DW, Scheimberg L, et al. New diagnostic crieria for multiple sclerosis:guidelines for research protocols. Ann. Neurol 1983;13:227-231.
8. Kurtzke JF. Rating neurologic impairment in multiuple sclerosis:na expanded disability status scale (EDSS) Neurology 1983;13:1444-1452.
9. Jacobs LD. Cookfair DL, Rudick RA et al. A phase III trial of intramuscular recombinant interferon beta as treatmento for exacerbation-remitting multiple sclerosis:design and conduct of study and baseline characteristics of patients. MS 1996;1, 118-135.
10. European Study Group on Interferon B 1b in Secondary Progressive MS. Placebo-controlled multicentre randomised trial of interferon 1 b in treatment of secundary progressive multiple sclerosis. Lancet 1998;352:14911497.
11. Jacobs LD, Cookfair DL, Rudick RA. et al. Intramuscular interferon beta 1 a for disease progression in relapsing multiple sclerosis. Ann. Neurol. 1996;39:285-294.
12. Sipe JC, Knobler RL, Braheny GPA, Rice HS, Oldstone, MBA. - A neurological rating scale (NRS) for use in multiple sclerosis. Neurology 1984;34:1368-1372.
13. PRIMS (Prevention of relapses and disability by interfern beta 1 a subcutaneously in Multiple Sclerosis Group). Randomized double/blind placebo -controled study of interferon beta 1-a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1510.
14. McFarlin De, McFarland HF. Multiple sclerosis. N Engl J Med. 1982;307:1183-1138.
15. Montezuma De, Carallo MJ. A treatment for the chronic disabilities of stable multiple sclerosis. Acta Medicotech 1983;3:155-160.
16. Goodkinn De. MS clinical trial design for the future MS 1996;1:393-399.
17. Cook SD, Dowling PC. Multiple sclerosis and viruses:an overview. Neurology 1980;30:80-91.
18. Steinman LS, Sriram S. In vivo effects of antibodies to immune response gene products:prevention of experimental allergic encephalomyelitis. Proc. Natl Acad Sci 1981;78:7111-7114.
19. Steinman LS, Sriram S. Experimental allergic encephalomyelitis:effects of antibodies. Proc. Natl Acad Sci 1983;82:5112-5120.
20. Ransohoff RM. Interferon beta specifically inhibits interferon gama induced class II major histocompatibility complex gene transcription in a human astrocytoma cell line. J. Neuroimmunol 1991;33:103-112.
21. Bever CT, Whitaker JN. Proteinases in inflammatory demyelinating disease, Springer Semin Immunopathol 1985;8:235-250.
22. Wucherpfennig KW, Weiner HL, Hafler DA. T cell recognition of myelin protein. Immunol. Today 1991;277-282.
23. Jacobs L, Munschauer FE. Intrathecal interferon in multiple sclerosis. Arch Neurol 1982;39:609-615.
24. Jacobs L, Fischer JS. Multicenter double-blind study of effect of intrathecally administered natural human fibroblast interferon on exacerbations of multiple sclerosis. Lancet 1986;2:1411-1414.
25. Ransohoff RM, Tuohy V, Lehmann P. The immunology of multiple sclerosis. New intricacies and new insights. J. Neuroimmunol. 1991;33:103-112.
26. Panitch HS, Milo R. Interferon therapy for multiple sclerosis. Int MSJ 1995;2:13-25.
27. Tilbery CP, Felipe E, Mendes MF. Uso do interferon beta natural na csclerose múltipla: resultados preliminares. Ver Bras Neurol. 1997;33:269-272.
28. Fieschi C, Pozzilli C, Bastianello S, et al. Human recombinant interferon beta in the treatment of relapsing-remitting multiple sclerosis:preliminary observations. MS 1995:1(Suppl):28-31.
29. Panitch HS, Bever CT. Clinical trials of interferons in multiple sclerosis. What have we learned ? J Neuroimmunol. 1993;46:155-164.
30. Rothman KJ, Michels KB. The continuing unethical use of placebo controls. J Med Ethics 1993;19:219-222.
31. Bahlman W. Innovative combination clinical trial designs/ pattient compliance:a community perspective. Antiviral Res. 1996;29:115-117.
32. Offenbacher H, Fazekas F, Schmidt R. Assesment of MRI criteria for a diagnosis of multiple sclerosis. Neurology 1993;43:905-909.
33. Tas MW, Barkhof F, van Wulderveen MAA. Gadolinium enhancement increases the specificity of MRI in the early diagnosis of MS. Radiology 1992;182:483-491.
34. Koopmans RA, Paty DW. Magnetic resonance imaging as na outcome in the treatment of multiple sclerosis:results of the interferon trial. MS 1995:1(Suppl):22-23.
35. Bornstein MB, Miller A, Slagle S et al. A pilot trial of copolymer in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-414.
36. Sharrack B, Hughes RC. Clinical scales for multiple slerosis. J. Neurol, Sci. 1996;135:1-9.
37. Martinez-Cáceres EM, Rio J, Barrau M. et al. Amelioration of flulike symptoms at the onset of interferon b 1 b therapy in multiple sclerosis by low dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol 1998;44:682-685.
38. Rio J, Nos C, Marzo ME et al. Low-dose steroids reduce flu-like symptoms at the initiation of IFNB-1b in relapsing-remitting MS. Neurology 1998;50:1910-1912.